CN1285335C - Pyrithioxine hydrochloride freeze-dried composition and its preparing method - Google Patents
Pyrithioxine hydrochloride freeze-dried composition and its preparing method Download PDFInfo
- Publication number
- CN1285335C CN1285335C CN 200410017640 CN200410017640A CN1285335C CN 1285335 C CN1285335 C CN 1285335C CN 200410017640 CN200410017640 CN 200410017640 CN 200410017640 A CN200410017640 A CN 200410017640A CN 1285335 C CN1285335 C CN 1285335C
- Authority
- CN
- China
- Prior art keywords
- divalvon
- pyrithioxin
- freeze
- dihydrochloride
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 229960004986 pyritinol Drugs 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims abstract description 10
- 239000008215 water for injection Substances 0.000 claims abstract description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 20
- 238000000859 sublimation Methods 0.000 claims description 18
- 230000008022 sublimation Effects 0.000 claims description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- HRZWYHGGJOWGRI-UHFFFAOYSA-N Pyrithioxin dihydrochloride Chemical compound Cl.Cl.OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO HRZWYHGGJOWGRI-UHFFFAOYSA-N 0.000 abstract 12
- 239000000463 material Substances 0.000 abstract 8
- 238000013329 compounding Methods 0.000 abstract 1
- 238000005286 illumination Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000012456 homogeneous solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Natural law | Character | Content (%) | Related substance (%) | Clarity of solution and color | Clarity |
0 | The white block | 99.58 | 0.30 | Up to specification | Up to specification |
4500LX illumination in 10 days | The white block | 99.46 | 0.32 | Up to specification | Up to specification |
High temperature was 60 ℃ in 10 days | The white block | 99.51 | 0.36 | Up to specification | Up to specification |
Natural law | Character | Content (%) | Related substance (%) | Clarity of solution and color | Clarity |
0 | The white block | 99.64 | 0.38 | Up to specification | Up to specification |
4500LX illumination in 10 days | The white block | 99.50 | 0.44 | Up to specification | Up to specification |
High temperature was 60 ℃ in 10 days | The white block | 99.42 | 0.35 | Up to specification | Up to specification |
Natural law | Character | Content (%) | Related substance (%) | Clarity of solution and color | Clarity |
0 | The white block | 99.28 | 0.32 | Up to specification | Up to specification |
4500LX illumination in 10 days | The white block | 99.35 | 0.34 | Up to specification | Up to specification |
High temperature was 60 ℃ in 10 days | The white block | 99.24 | 0.35 | Up to specification | Up to specification |
Natural law | Character | Content (%) | Related substance (%) | Clarity of solution and color | Clarity |
0 | The white block | 99.54 | 0.34 | Up to specification | Up to specification |
4500LX illumination in 10 days | The white block | 99.58 | 0.33 | Up to specification | Up to specification |
High temperature was 60 ℃ in 10 days | The white block | 99.42 | 0.30 | Up to specification | Up to specification |
Natural law | Character | Content (%) | Related substance (%) | Clarity of solution and color | Clarity |
0 | The white block | 99.15 | 0.30 | Up to specification | Up to specification |
4500LX illumination in 10 days | The white block | 99.08 | 0.36 | Up to specification | Up to specification |
High temperature was 60 ℃ in 10 days | The white block | 99.16 | 0.32 | Up to specification | Up to specification |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410017640 CN1285335C (en) | 2004-04-13 | 2004-04-13 | Pyrithioxine hydrochloride freeze-dried composition and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410017640 CN1285335C (en) | 2004-04-13 | 2004-04-13 | Pyrithioxine hydrochloride freeze-dried composition and its preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1562007A CN1562007A (en) | 2005-01-12 |
CN1285335C true CN1285335C (en) | 2006-11-22 |
Family
ID=34479076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410017640 Expired - Fee Related CN1285335C (en) | 2004-04-13 | 2004-04-13 | Pyrithioxine hydrochloride freeze-dried composition and its preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1285335C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12065264B2 (en) | 2014-06-11 | 2024-08-20 | Earthstone International Llc | Method for using a foamed glass composite material |
US12071259B2 (en) | 2022-04-06 | 2024-08-27 | Earthstone International Llc | Foamed glass composite material and a method using the same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101164619B (en) * | 2006-10-20 | 2011-05-18 | 山东轩竹医药科技有限公司 | Pyritinol injection with special purpose solvent |
CN101810614B (en) * | 2010-04-15 | 2012-06-20 | 杭州康泉德投资管理有限公司 | Stable pyritinol hydrochloride composition for injection and preparation and preparation method thereof |
-
2004
- 2004-04-13 CN CN 200410017640 patent/CN1285335C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12065264B2 (en) | 2014-06-11 | 2024-08-20 | Earthstone International Llc | Method for using a foamed glass composite material |
US12071259B2 (en) | 2022-04-06 | 2024-08-27 | Earthstone International Llc | Foamed glass composite material and a method using the same |
Also Published As
Publication number | Publication date |
---|---|
CN1562007A (en) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102872011A (en) | Pharmaceutical composition comprising (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide | |
TW201219375A (en) | Sodium salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide | |
JP2020511417A (en) | Pharmaceutical composition of sulfonylurea drug and method for preparing the same | |
CN102133199A (en) | Doxofylline lyophilized preparation for injection and preparation method thereof | |
CN105078905A (en) | Preparation method of doxycycline hyclate freeze-dried powder injection | |
KR101468153B1 (en) | 5α-ANDROSTANE-3β,5,6β-TRIOL INJECTION AND PREPARATION METHOD THEREFOR | |
CN1285335C (en) | Pyrithioxine hydrochloride freeze-dried composition and its preparing method | |
CN106265536A (en) | Bortezomib pharmaceutical composition and preparation method thereof | |
JP5070670B2 (en) | N- [o- (p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate freeze-dried preparation and method for producing the same | |
CN111904936A (en) | Famotidine freeze-dried powder injection | |
CN106309385A (en) | Bortezomib freeze-dried powder injection and preparation process thereof | |
CN101444479A (en) | Lapatinib injection and preparation method thereof | |
CN103462909B (en) | Formulation of nizatidine for injection and preparation technology thereof | |
CN107595787A (en) | A kind of preparation method of the double meglumine lyophilized formulations of injection Fosaprepitant | |
CN114159396A (en) | Espressol omeprazole sodium freeze-dried preparation for injection and preparation method thereof | |
CN109044969B (en) | Preparation method of paclitaxel injection | |
CN1230175C (en) | Ligustrazine hydrochloride freeze-dried preparation for injection and its preparing method | |
CN1161121C (en) | Alkaloid of matrine category utilized for mainline and its preparation method | |
CN106176626B (en) | L-alanine- (14-oridonin) ester parenteral pharmaceutical composition | |
CN101455646A (en) | Meclofenoxate hydrochloride preparation freeze-drying technique and preparation method thereof | |
CN1686140A (en) | Valacyclovir hydrochloride freeze dried preparation and its preparation method | |
CN106924195B (en) | Freeze-drying process of paclitaxel liposome composition for injection | |
CN1695613A (en) | Injection of sodium ascorbate and preparation method | |
CN108272755B (en) | A kind of hydrochloride for injection mycophenolate mofetil lyophilized preparation and preparation method thereof | |
CN111465389A (en) | Pharmaceutical composition of docetaxel conjugate and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG JIANFENG MEDICINE CO., LTD.; JIN SANJIU Free format text: FORMER OWNER: JIN SANJIU Effective date: 20070427 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070427 Address after: 322000 Jinhua Industrial Park, Zhejiang Co-patentee after: Jin Sanjiu Patentee after: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Address before: Hangzhou City, Zhejiang province 310003 Phoenix Road No. 68 East 1307 building A Patentee before: Jin Sanjiu |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hangzhou tiger Pharmaceutical Technology Co., Ltd. Assignor: Jin Sanjiu Contract fulfillment period: 2006.7.22 to 2012.7.21 Contract record no.: 2008330000943 Denomination of invention: Pyrithioxine hydrochloride freeze-dried composition and its preparing method Granted publication date: 20061122 License type: Exclusive license Record date: 20081010 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2006.7.22 TO 2012.7.21; CHANGE OF CONTRACT Name of requester: HANGZHOU TIGER PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20081010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090320 Address after: Post editor in industrial park of Jinhua, Zhejiang: 322000 Co-patentee after: Hangzhou tiger Pharmaceutical Technology Co., Ltd. Patentee after: Zhejiang Jianfeng Pharmaceutical Co., Ltd. Address before: Post editor in industrial park of Jinhua, Zhejiang: 322000 Co-patentee before: Jin Sanjiu Patentee before: Zhejiang Jianfeng Pharmaceutical Co., Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 322000 Jinhua Industrial Park, Zhejiang Co-patentee after: Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. Patentee after: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Address before: 322000 Jinhua Industrial Park, Zhejiang Co-patentee before: Hangzhou tiger Pharmaceutical Technology Co., Ltd. Patentee before: Zhejiang Jiafeng Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061122 Termination date: 20190413 |